Marsh McLennan and Its Businesses Will Brand as Marsh
14.10.2025 14:15:00 EEST | Business Wire | Press release
Marsh McLennan (NYSE: MMC) today announced that it will change its brand to Marsh effective January 2026, and it has created a new unit, Business and Client Services (BCS), to accelerate innovation and centralize investments in operational excellence, data, AI and analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013772875/en/
Marsh McLennan and its businesses will brand as Marsh. The new Marsh brand comes to life with a new logo – a bold design that represents the unique perspectives the Company offers.
“In an increasingly complex environment, clients are seeking advice, solutions and insights that draw on expertise from across our firm,” said John Doyle, President and CEO of Marsh McLennan. “The changes we announce today reflect the way we continue to bring our Company together to better help our clients overcome challenges and find opportunity.”
The new Marsh brand
The new Marsh brand will represent the Company’s market-leading, specialized capabilities across risk, reinsurance and capital, people and investments, and management consulting, and reflects the Company’s continued evolution to become increasingly impactful for its clients. The Company’s four businesses will adopt the Marsh brand beginning in 2027, following a transition period.
“Today, Marsh stands for excellence in risk advising and insurance broking. The new Marsh brand will also symbolize everything our company has to offer: a distinct combination of capabilities in professional services, scale and specialization for clients, enabled by cutting-edge AI and analytics,” said Mr. Doyle.
“Unifying under one brand will accelerate the impact we deliver to the marketplace and give clients even greater confidence to thrive through the power of perspective,” said John Jones, Chief Marketing and Communications Officer of Marsh McLennan.
“The new Marsh brand comes to life with a new logo – a bold design that represents the greater impact we can have with clients and the unique perspectives we offer,” said Mr. Jones.
After the transition period, Marsh and Mercer will each go to market under the new Marsh brand. Guy Carpenter will be Marsh Re. Oliver Wyman will go to market as Oliver Wyman, a Marsh business, while the operating unit Oliver Wyman Group will become Marsh Management Consulting.
The Company’s stock ticker symbol will become “MRSH” in January 2026.
Business and Client Services
BCS brings together the firm’s technology, data and operations teams under the leadership of Paul Beswick, Marsh McLennan’s Chief Information and Operations Officer. Through BCS, the Company will create a data and technology ecosystem that harnesses AI and other technologies to enhance client outcomes across its businesses while delivering operational excellence and efficiency.
“The rapid development of AI, and the insights it can derive from our data, will help unlock new opportunities for our clients and colleagues,” said Mr. Beswick. “By harnessing this powerful tool to simplify operations and elevate service quality, we will drive innovation and deliver efficiencies to reinvest in client value and growth.”
“With the changes announced today, our brand will embody the greater value we can create for all our stakeholders, while BCS will drive enhanced client service. Both initiatives reflect our steadfast commitment to delivering meaningful outcomes and exceptional experiences for our clients and colleagues," said Mr. Doyle.
About Marsh McLennan
Marsh McLennan (NYSE: MMC) is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of over $24 billion and more than 90,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit marshmclennan.com, or follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013772875/en/
Contacts
Media Contact:
Erick Gustafson
Marsh McLennan
+1 202 263 7788
erick.gustafson@mmc.com
Investor Contact:
Jay Gelb
Marsh McLennan
+1 212 345 1569
jay.gelb@mmc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i
Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release
Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom